rss
04-30-2015, 11:31 PM
Implant Delivers Antiretroviral Drug to Stop Spread of HIV
http://cdn.medgadget.com/wp-content/uploads/2015/04/hiv-implant.jpg
Antiretroviral ***** require patients to adhere to a strict dosing regimen, but as with other diseases patients tend to slack off, often paying a high price. Researchers*at the Oak Crest Institute of Science in Pasadena, California have developed a small implant that can deliver*te**fovir alafenamide fumarate, a prodrug developed by Gilead Sciences to help treat and prevent HIV infection, in a controlled manner.
The device looks like the **w commonly available subdermal contraception implants and releases its cargo evenly over a period of 40 days. It was tested on dogs to see whether there are any side effects, the researchers **t detecting any adverse events in the study. It’s **w hoped that the tech**logy may soon be made available for at-risk populations, as the drug is looking very promising as a prophylaxis for HIV, as well as for treatment of infected patients.
Some details from the study in*journal Antimicrobial Agents and Chemotherapy
A candidate device delivering TAF at 0.92 mg d-1 in vitro was evaluated in beagle dogs over 40 d for pharmacokinetics and preliminary safety. ** adverse events related to treatment with the test article were **ted during the course of the study and ** significant, unusual ab**rmalities were observed. The implant maintained a low systemic exposure to TAF (median 0.85 ng ml-1, IQR 0.60-1.50 ng ml-1) and te**fovir (TFV, median 15.0 ng ml-1, IQR 8.8-23.3 ng ml-1), the product of in vivoTAF hydrolysis. High concentrations (median 512 fmol/106 cells over the first 35 days) of the pharmacologically active metabolite, TFV diphosphate, were observed in peripheral blood mo**nuclear cells, levels over 30 times higher than those associated with HIV-1 PrEP efficacy in humans.
Study in*Antimicrobial Agents and Chemotherapy: Pharmacokinetics of Long-acting Te**fovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis… (http://aac.asm.org/content/early/2015/04/14/AAC.00656-15)
Source: Oak Crest Institute of Science… (http://oak-crest.org/oakcrest-news/stopping-hiv-in-its-tracks/)
The post Implant Delivers Antiretroviral Drug to Stop Spread of HIV (http://www.medgadget.com/2015/04/implant-delivers-antiretroviral-drug-to-stop-spread-of-hiv.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=LTJJEDvpX6M:IV_RTxEUNGw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=LTJJEDvpX6M:IV_RTxEUNGw:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=LTJJEDvpX6M:IV_RTxEUNGw:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=LTJJEDvpX6M:IV_RTxEUNGw:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/LTJJEDvpX6M
http://cdn.medgadget.com/wp-content/uploads/2015/04/hiv-implant.jpg
Antiretroviral ***** require patients to adhere to a strict dosing regimen, but as with other diseases patients tend to slack off, often paying a high price. Researchers*at the Oak Crest Institute of Science in Pasadena, California have developed a small implant that can deliver*te**fovir alafenamide fumarate, a prodrug developed by Gilead Sciences to help treat and prevent HIV infection, in a controlled manner.
The device looks like the **w commonly available subdermal contraception implants and releases its cargo evenly over a period of 40 days. It was tested on dogs to see whether there are any side effects, the researchers **t detecting any adverse events in the study. It’s **w hoped that the tech**logy may soon be made available for at-risk populations, as the drug is looking very promising as a prophylaxis for HIV, as well as for treatment of infected patients.
Some details from the study in*journal Antimicrobial Agents and Chemotherapy
A candidate device delivering TAF at 0.92 mg d-1 in vitro was evaluated in beagle dogs over 40 d for pharmacokinetics and preliminary safety. ** adverse events related to treatment with the test article were **ted during the course of the study and ** significant, unusual ab**rmalities were observed. The implant maintained a low systemic exposure to TAF (median 0.85 ng ml-1, IQR 0.60-1.50 ng ml-1) and te**fovir (TFV, median 15.0 ng ml-1, IQR 8.8-23.3 ng ml-1), the product of in vivoTAF hydrolysis. High concentrations (median 512 fmol/106 cells over the first 35 days) of the pharmacologically active metabolite, TFV diphosphate, were observed in peripheral blood mo**nuclear cells, levels over 30 times higher than those associated with HIV-1 PrEP efficacy in humans.
Study in*Antimicrobial Agents and Chemotherapy: Pharmacokinetics of Long-acting Te**fovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis… (http://aac.asm.org/content/early/2015/04/14/AAC.00656-15)
Source: Oak Crest Institute of Science… (http://oak-crest.org/oakcrest-news/stopping-hiv-in-its-tracks/)
The post Implant Delivers Antiretroviral Drug to Stop Spread of HIV (http://www.medgadget.com/2015/04/implant-delivers-antiretroviral-drug-to-stop-spread-of-hiv.html) appeared first on Medgadget (http://www.medgadget.com).
http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA (http://feeds.feedburner.com/~ff/Medgadget?a=LTJJEDvpX6M:IV_RTxEUNGw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs (http://feeds.feedburner.com/~ff/Medgadget?a=LTJJEDvpX6M:IV_RTxEUNGw:qj6IDK7rITs) http://feeds.feedburner.com/~ff/Medgadget?i=LTJJEDvpX6M:IV_RTxEUNGw:gIN9vFwOqvQ (http://feeds.feedburner.com/~ff/Medgadget?a=LTJJEDvpX6M:IV_RTxEUNGw:gIN9vFwOqvQ)
http://feeds.feedburner.com/~r/Medgadget/~4/LTJJEDvpX6M